{"id":264272,"date":"2026-09-23T12:49:26","date_gmt":"2026-09-23T07:19:26","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=264272"},"modified":"2026-09-23T12:49:26","modified_gmt":"2026-09-23T07:19:26","slug":"dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-technologies","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-technologies\/","title":{"rendered":"Dr Lal PathLabs vs Metropolis Healthcare vs Thyrocare Technologies: Which Stock Should You Track"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Dr Lal PathLabs PE 58.71, mkt cap Rs 32,077 crore. Metropolis Healthcare PE 60.47, mkt cap Rs 12,268 crore. Thyrocare Technologies PE 52.23, mkt cap Rs 9,186 crore.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Dr Lal PathLabs vs Metropolis Healthcare vs Thyrocare Technologies is a side-by-side comparison of three companies from the Diagnostics space. On this comparison, Dr Lal PathLabs carries a market capitalisation of about Rs 32,077 crore against Rs 12,268 crore for Metropolis Healthcare and Rs 9,186 crore for Thyrocare Technologies, with return on equity of 20.13%, 12.56% and 27.85% respectively. Each company&#8217;s numbers are presented here without a declared better pick, since the right stock depends on an investor&#8217;s own criteria.<\/p>\n<\/div>\n<p>Dr Lal PathLabs vs Metropolis Healthcare vs Thyrocare Technologies starts with the core numbers most investors compare within the Diagnostics segment: market capitalisation, valuation multiples, profitability and dividend yield. Figures below are sourced as of September 2026 and will shift with daily price moves.<\/p>\n<p>All three names sit in the Diagnostics bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-technologies\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-technologies\/#Dr_Lal_PathLabs_Metropolis_Healthcare_and_Thyrocare_Technologies_Company_Overview\" title=\"Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies: Company Overview\">Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies: Company Overview<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-technologies\/#Dr_Lal_PathLabs_vs_Metropolis_Healthcare_vs_Thyrocare_Technologies_Valuation_and_Profitability_Snapshot\" title=\"Dr Lal PathLabs vs Metropolis Healthcare vs Thyrocare Technologies: Valuation and Profitability Snapshot\">Dr Lal PathLabs vs Metropolis Healthcare vs Thyrocare Technologies: Valuation and Profitability Snapshot<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-technologies\/#Dr_Lal_PathLabs_vs_Metropolis_Healthcare_vs_Thyrocare_Technologies_Latest_Quarterly_Results\" title=\"Dr Lal PathLabs vs Metropolis Healthcare vs Thyrocare Technologies: Latest Quarterly Results\">Dr Lal PathLabs vs Metropolis Healthcare vs Thyrocare Technologies: Latest Quarterly Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-technologies\/#What_Should_Investors_Look_at_Beyond_These_Numbers\" title=\"What Should Investors Look at Beyond These Numbers?\">What Should Investors Look at Beyond These Numbers?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-technologies\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-technologies\/#FAQs_on_Dr_Lal_PathLabs_vs_Metropolis_Healthcare_vs_Thyrocare_Technologies\" title=\"FAQs on Dr Lal PathLabs vs Metropolis Healthcare vs Thyrocare Technologies\">FAQs on Dr Lal PathLabs vs Metropolis Healthcare vs Thyrocare Technologies<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-technologies\/#What_is_the_market_cap_difference_between_Dr_Lal_PathLabs_Metropolis_Healthcare_and_Thyrocare_Technologies\" title=\"What is the market cap difference between Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies?\">What is the market cap difference between Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-technologies\/#Which_of_the_three_has_the_highest_PE_ratio\" title=\"Which of the three has the highest PE ratio?\">Which of the three has the highest PE ratio?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-technologies\/#Which_of_the_three_has_the_highest_ROE\" title=\"Which of the three has the highest ROE?\">Which of the three has the highest ROE?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-technologies\/#Which_of_these_three_stocks_pays_the_highest_dividend_yield\" title=\"Which of these three stocks pays the highest dividend yield?\">Which of these three stocks pays the highest dividend yield?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-technologies\/#What_is_the_debt_to_equity_ratio_for_Dr_Lal_PathLabs_Metropolis_Healthcare_and_Thyrocare_Technologies\" title=\"What is the debt to equity ratio for Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies?\">What is the debt to equity ratio for Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-technologies\/#Which_of_the_three_trades_at_the_highest_price_to_book_value\" title=\"Which of the three trades at the highest price to book value?\">Which of the three trades at the highest price to book value?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-technologies\/#Is_one_of_Dr_Lal_PathLabs_Metropolis_Healthcare_or_Thyrocare_Technologies_better_than_the_others\" title=\"Is one of Dr Lal PathLabs, Metropolis Healthcare or Thyrocare Technologies better than the others?\">Is one of Dr Lal PathLabs, Metropolis Healthcare or Thyrocare Technologies better than the others?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Dr_Lal_PathLabs_Metropolis_Healthcare_and_Thyrocare_Technologies_Company_Overview\"><\/span><strong>Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies: Company Overview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Dr Lal PathLabs<\/strong> is a listed Indian company in the Diagnostics space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.<\/p>\n<p><strong>Metropolis Healthcare<\/strong> is a listed Indian company in the Diagnostics space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.<\/p>\n<p><strong>Thyrocare Technologies<\/strong> is a listed Indian company in the Diagnostics space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dr_Lal_PathLabs_vs_Metropolis_Healthcare_vs_Thyrocare_Technologies_Valuation_and_Profitability_Snapshot\"><\/span><strong>Dr Lal PathLabs vs Metropolis Healthcare vs Thyrocare Technologies: Valuation and Profitability Snapshot<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th><a href=\"https:\/\/univest.in\/stocks\/lalpathlab\/dr-lal-pathlabs-ltd-share-price-today\">Dr Lal PathLabs<\/a><\/th>\n<th><a href=\"https:\/\/univest.in\/stocks\/metropolis\/metropolis-healthcare-ltd-share-price-today\">Metropolis Healthcare<\/a><\/th>\n<th><a href=\"https:\/\/univest.in\/stocks\/thyrocare\/thyrocare-technologies-ltd-share-price-today\">Thyrocare Technologies<\/a><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Market Cap (approx.)<\/td>\n<td>Rs 32,077 crore<\/td>\n<td>Rs 12,268 crore<\/td>\n<td>Rs 9,186 crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio (TTM)<\/td>\n<td>58.71<\/td>\n<td>60.47<\/td>\n<td>52.23<\/td>\n<\/tr>\n<tr>\n<td>PB Ratio<\/td>\n<td>12.79<\/td>\n<td>8.17<\/td>\n<td>17.92<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity (ROE)<\/td>\n<td>20.13%<\/td>\n<td>12.56%<\/td>\n<td>27.85%<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM, Rs)<\/td>\n<td>32.55<\/td>\n<td>9.78<\/td>\n<td>11.05<\/td>\n<\/tr>\n<tr>\n<td>Dividend Yield<\/td>\n<td>1.07%<\/td>\n<td>0.85%<\/td>\n<td>2.43%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.08<\/td>\n<td>0.15<\/td>\n<td>0.09<\/td>\n<\/tr>\n<tr>\n<td>Book Value per Share (Rs)<\/td>\n<td>149.45<\/td>\n<td>72.41<\/td>\n<td>32.21<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for Live Data<\/strong><\/a><\/p>\n<p>On valuation, Dr Lal PathLabs trades at a PE of 58.71 and a PB of 12.79, Metropolis Healthcare at a PE of 60.47 and a PB of 8.17, while Thyrocare Technologies trades at a PE of 52.23 and a PB of 17.92. On return on equity, the three post 20.13%, 12.56% and 27.85% respectively, and on dividend yield they stand at 1.07%, 0.85% and 2.43%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dr_Lal_PathLabs_vs_Metropolis_Healthcare_vs_Thyrocare_Technologies_Latest_Quarterly_Results\"><\/span><strong>Dr Lal PathLabs vs Metropolis Healthcare vs Thyrocare Technologies: Latest Quarterly Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Company<\/th>\n<th>Latest Quarter Revenue<\/th>\n<th>Latest Quarter Net Profit<\/th>\n<th>YoY Change (Revenue)<\/th>\n<th>QoQ Change (Revenue)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Dr Lal PathLabs<\/td>\n<td>Rs 829.60 crore<\/td>\n<td>Rs 170.50 crore<\/td>\n<td>+18.9%<\/td>\n<td>+14.2%<\/td>\n<\/tr>\n<tr>\n<td>Metropolis Healthcare<\/td>\n<td>Rs 455.32 crore<\/td>\n<td>Rs 56.88 crore<\/td>\n<td>+15.7%<\/td>\n<td>+5.2%<\/td>\n<\/tr>\n<tr>\n<td>Thyrocare Technologies<\/td>\n<td>Rs 244.17 crore<\/td>\n<td>Rs 51.33 crore<\/td>\n<td>+23.5%<\/td>\n<td>+7.0%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Quarterly figures above are the most recent reported quarter for each company (Q1 FY28, quarter ended June 2026), compared with the year-ago and preceding quarter.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies live prices.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Should_Investors_Look_at_Beyond_These_Numbers\"><\/span><strong>What Should Investors Look at Beyond These Numbers?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Beyond the metrics above, investors comparing these three diagnostics names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and any sector-specific regulatory developments, since a single-quarter snapshot can shift quickly.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Dr Lal PathLabs vs Metropolis Healthcare vs Thyrocare Technologies highlights how differently three companies in the same diagnostics segment can score across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information as of September 2026 and may not reflect real-time prices. Please verify all data independently before making any investment decision. This comparison does not recommend or endorse any single stock over another; investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Dr_Lal_PathLabs_vs_Metropolis_Healthcare_vs_Thyrocare_Technologies\"><\/span><strong>FAQs on Dr Lal PathLabs vs Metropolis Healthcare vs Thyrocare Technologies<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_market_cap_difference_between_Dr_Lal_PathLabs_Metropolis_Healthcare_and_Thyrocare_Technologies\"><\/span><strong>What is the market cap difference between Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of September 2026, Dr Lal PathLabs has a market cap of approximately Rs 32,077 crore, Metropolis Healthcare is at approximately Rs 12,268 crore, and Thyrocare Technologies is at approximately Rs 9,186 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_of_the_three_has_the_highest_PE_ratio\"><\/span><strong>Which of the three has the highest PE ratio?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Among Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies, the PE ratios stand at 58.71, 60.47 and 52.23 respectively as of September 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_of_the_three_has_the_highest_ROE\"><\/span><strong>Which of the three has the highest ROE?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies post ROE of 20.13%, 12.56% and 27.85% respectively as of September 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_of_these_three_stocks_pays_the_highest_dividend_yield\"><\/span><strong>Which of these three stocks pays the highest dividend yield?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies carry dividend yields of 1.07%, 0.85% and 2.43% respectively.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_debt_to_equity_ratio_for_Dr_Lal_PathLabs_Metropolis_Healthcare_and_Thyrocare_Technologies\"><\/span><strong>What is the debt to equity ratio for Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dr Lal PathLabs carries a debt to equity of 0.08, Metropolis Healthcare of 0.15, and Thyrocare Technologies of 0.09.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_of_the_three_trades_at_the_highest_price_to_book_value\"><\/span><strong>Which of the three trades at the highest price to book value?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies trade at price to book ratios of 12.79, 8.17 and 17.92 respectively.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_one_of_Dr_Lal_PathLabs_Metropolis_Healthcare_or_Thyrocare_Technologies_better_than_the_others\"><\/span><strong>Is one of Dr Lal PathLabs, Metropolis Healthcare or Thyrocare Technologies better than the others?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This comparison does not declare one stock better than another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor&#8217;s own criteria and research.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the market cap difference between Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of September 2026, Dr Lal PathLabs has a market cap of approximately Rs 32,077 crore, Metropolis Healthcare is at approximately Rs 12,268 crore, and Thyrocare Technologies is at approximately Rs 9,186 crore.\"}},{\"@type\":\"Question\",\"name\":\"Which of the three has the highest PE ratio?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Among Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies, the PE ratios stand at 58.71, 60.47 and 52.23 respectively as of September 2026.\"}},{\"@type\":\"Question\",\"name\":\"Which of the three has the highest ROE?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies post ROE of 20.13%, 12.56% and 27.85% respectively as of September 2026.\"}},{\"@type\":\"Question\",\"name\":\"Which of these three stocks pays the highest dividend yield?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies carry dividend yields of 1.07%, 0.85% and 2.43% respectively.\"}},{\"@type\":\"Question\",\"name\":\"What is the debt to equity ratio for Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Dr Lal PathLabs carries a debt to equity of 0.08, Metropolis Healthcare of 0.15, and Thyrocare Technologies of 0.09.\"}},{\"@type\":\"Question\",\"name\":\"Which of the three trades at the highest price to book value?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Dr Lal PathLabs, Metropolis Healthcare and Thyrocare Technologies trade at price to book ratios of 12.79, 8.17 and 17.92 respectively.\"}},{\"@type\":\"Question\",\"name\":\"Is one of Dr Lal PathLabs, Metropolis Healthcare or Thyrocare Technologies better than the others?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This comparison does not declare one stock better than another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor's own criteria and research.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dr Lal PathLabs vs Metropolis Healthcare vs Thyrocare Technologies compared on market cap, PE, PB, ROE, dividend yield and debt to equity, as of September 2026.<\/p>\n","protected":false},"author":29,"featured_media":264269,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[6920,1019],"class_list":["post-264272","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-diagnostics","tag-stock-market"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["264269"],"rank_math_title":["Dr Lal PathLabs vs Metropolis Healthcare vs Thyrocare Technologie"],"rank_math_description":["Dr Lal PathLabs vs Metropolis Healthcare vs Thyrocare Technologies compared on market cap, PE, PB, ROE, dividend yield and debt to equity, as of September 2026."],"rank_math_focus_keyword":["Dr Lal PathLabs vs Metropolis Healthcare vs Thyrocare Technologies"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/09\/dr-lal-pathlabs-vs-metropolis-healthcare-vs-thyrocare-technologies-which-stock.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/264272","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=264272"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/264272\/revisions"}],"predecessor-version":[{"id":264274,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/264272\/revisions\/264274"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/264269"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=264272"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=264272"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=264272"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}